Centene Shares Drop 11% After CEO Warns of ACA Headwinds
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Should l Buy CNC?
Source: seekingalpha
- Significant Stock Decline: Centene (CNC) shares plummeted approximately 11% on Tuesday after CEO Sarah London warned at the Barclays Healthcare Conference about persistent headwinds in the Affordable Care Act marketplace operations, which could undermine investor confidence and affect the company's financing capabilities in the short term.
- Strong Ratings Persist: Despite the stock drop, Seeking Alpha's Quant Ratings still ranks Centene as the top U.S. managed health care stock with a score of 4.31, indicating its relative strength in the market and being the only company to receive a 'Buy' rating, reflecting market recognition of its long-term potential.
- Competitor Performance: Following Centene, Alignment Healthcare (ALHC) and UnitedHealth Group (UNH) scored 3.32 and 3.28 respectively, indicating relatively lower market confidence in these competitors, which may impact their future market share.
- Market Environment Challenges: With the Trump administration planning to withhold $259 million in Medicaid payments to Minnesota, the external challenges faced by Centene could intensify, further affecting its operational performance and profitability in the ACA market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNC
Wall Street analysts forecast CNC stock price to rise
15 Analyst Rating
5 Buy
8 Hold
2 Sell
Hold
Current: 36.400
Low
32.00
Averages
43.07
High
59.00
Current: 36.400
Low
32.00
Averages
43.07
High
59.00
About CNC
Centene Corporation is a healthcare company. The Company provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Its segments include Medicaid, Medicare, Commercial and Other. Specifically, the Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Centene Reaffirms 2026 Earnings Guidance at Barclays Conference
- Earnings Guidance Reaffirmed: At the Barclays 28th Annual Global Healthcare Conference, Centene expects to reaffirm its 2026 GAAP diluted earnings per share guidance of over $1.98 and adjusted diluted EPS of over $3.00, demonstrating the company's confidence in its future performance.
- Market Expectations Align: The company's earnings forecast aligns with market analysts' estimates, indicating Centene's stability and ongoing profitability in the healthcare insurance market, which may bolster investor confidence.
- Margin Improvement: Centene's aggressive repricing and cost-cutting measures have enhanced its margin of safety, indicating effective strategies to improve financial health, which could positively impact its stock price.
- Industry Dynamics Under Scrutiny: Centene, along with CVS Health and Elevance, has received subpoenas from a House panel, reflecting potential regulatory changes that could affect the company's operations and market positioning.
See More
Texas Welcomes 14th Foster Care Center of Excellence
- Foster Center Expansion: Superior HealthPlan has officially designated Cute Pediatrics as the 14th Foster Care Center of Excellence in Texas, marking the first recognition in the Rio Grande Valley and enhancing healthcare quality for foster children in the region.
- Healthcare Commitment: Cute Pediatrics focuses on providing comprehensive medical services for children from newborn to 21 years, particularly supporting high-risk newborns, ensuring every child’s long-term health and emotional well-being.
- Quality Standards Enhancement: To achieve this designation, Cute Pediatrics must meet over 30 criteria, including quality improvement initiatives and staff requirements, which not only elevate service quality but also strengthen Superior HealthPlan's leadership position in foster care healthcare.
- Community Contribution: Since 2020, Superior HealthPlan has contributed $12.3 million in grants and sponsorships to low-income communities, demonstrating its commitment to all 254 Texas counties and further solidifying its status as a leading managed care organization.
See More
Centene Shares Drop 11% After CEO Warns of ACA Headwinds
- Significant Stock Decline: Centene (CNC) shares plummeted approximately 11% on Tuesday after CEO Sarah London warned at the Barclays Healthcare Conference about persistent headwinds in the Affordable Care Act marketplace operations, which could undermine investor confidence and affect the company's financing capabilities in the short term.
- Strong Ratings Persist: Despite the stock drop, Seeking Alpha's Quant Ratings still ranks Centene as the top U.S. managed health care stock with a score of 4.31, indicating its relative strength in the market and being the only company to receive a 'Buy' rating, reflecting market recognition of its long-term potential.
- Competitor Performance: Following Centene, Alignment Healthcare (ALHC) and UnitedHealth Group (UNH) scored 3.32 and 3.28 respectively, indicating relatively lower market confidence in these competitors, which may impact their future market share.
- Market Environment Challenges: With the Trump administration planning to withhold $259 million in Medicaid payments to Minnesota, the external challenges faced by Centene could intensify, further affecting its operational performance and profitability in the ACA market.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
Bio-Techne and UnitedHealth Options Trading Activity Surges
- Bio-Techne Options Volume: Bio-Techne Corp (Ticker: TECH) has seen an options trading volume of 15,116 contracts today, equating to approximately 1.5 million shares, which represents a significant 62.4% of its average daily trading volume over the past month of 2.4 million shares.
- High Volume Contracts: Notably, the $60 strike call option for TECH has recorded a high volume of 5,055 contracts traded today, representing around 505,500 underlying shares, indicating strong market interest at this price level.
- UnitedHealth Options Activity: UnitedHealth Group Inc (Ticker: UNH) has reported an options trading volume of 39,170 contracts today, translating to approximately 3.9 million shares, which is about 47.5% of its average daily trading volume over the past month of 8.3 million shares, reflecting investor focus on its future performance.
- Key Contract Insights: The $300 strike call option for UNH has seen a trading volume of 2,172 contracts today, representing approximately 217,200 shares, suggesting bullish expectations in the market, potentially linked to anticipated future earnings performance.
See More
Centene Stock Declines Amid Membership Losses
- Stock Decline: Centene Corp (NYSE:CNC) shares fell 13.18% to $37.61 on Tuesday, reflecting a 35% drop over the past year, indicating market concerns regarding its future performance.
- Earnings Guidance Reaffirmed: Despite the pressures, Centene reaffirmed its 2026 earnings guidance of over $1.98 per share and adjusted earnings exceeding $3 per share, demonstrating the company's confidence in its future profitability.
- Membership Loss Warning: At the Barclays Global Healthcare Conference, Centene warned of lower membership in some Affordable Care Act (ACA) plans, with attrition expected between the high teens and mid-30s, as noted by CEO Sarah London, who indicated they might exceed this range.
- Increased Utilization Rates: Centene reported a decline in total membership from 28.60 million to 27.63 million for 2025, primarily due to a drop in Medicaid members from 13.00 million to 12.52 million, while higher utilization patterns were noted in specialty pharmacy within the silver tier, indicating shifts in market demand.
See More
Centene Reaffirms 2026 Earnings Guidance at Barclays Conference
- Earnings Guidance Reaffirmed: At the Barclays 28th Annual Global Healthcare Conference, Centene expects to reaffirm its 2026 GAAP diluted earnings per share guidance of over $1.98 and adjusted diluted EPS of over $3.00, demonstrating the company's confidence in its future performance.
- Market Expectations Align: The company's earnings forecast aligns with market analysts' estimates, indicating Centene's stability and ongoing profitability in the healthcare insurance market, which may bolster investor confidence.
- Margin Improvement: Centene's aggressive repricing and cost-cutting measures have enhanced its margin of safety, indicating effective strategies to improve financial health, which could positively impact its stock price.
- Industry Dynamics Under Scrutiny: Centene, along with CVS Health and Elevance, has received subpoenas from a House panel, reflecting potential regulatory changes that could affect the company's operations and market positioning.
See More
Texas Welcomes 14th Foster Care Center of Excellence
- Foster Center Expansion: Superior HealthPlan has officially designated Cute Pediatrics as the 14th Foster Care Center of Excellence in Texas, marking the first recognition in the Rio Grande Valley and enhancing healthcare quality for foster children in the region.
- Healthcare Commitment: Cute Pediatrics focuses on providing comprehensive medical services for children from newborn to 21 years, particularly supporting high-risk newborns, ensuring every child’s long-term health and emotional well-being.
- Quality Standards Enhancement: To achieve this designation, Cute Pediatrics must meet over 30 criteria, including quality improvement initiatives and staff requirements, which not only elevate service quality but also strengthen Superior HealthPlan's leadership position in foster care healthcare.
- Community Contribution: Since 2020, Superior HealthPlan has contributed $12.3 million in grants and sponsorships to low-income communities, demonstrating its commitment to all 254 Texas counties and further solidifying its status as a leading managed care organization.
See More
Centene Shares Drop 11% After CEO Warns of ACA Headwinds
- Significant Stock Decline: Centene (CNC) shares plummeted approximately 11% on Tuesday after CEO Sarah London warned at the Barclays Healthcare Conference about persistent headwinds in the Affordable Care Act marketplace operations, which could undermine investor confidence and affect the company's financing capabilities in the short term.
- Strong Ratings Persist: Despite the stock drop, Seeking Alpha's Quant Ratings still ranks Centene as the top U.S. managed health care stock with a score of 4.31, indicating its relative strength in the market and being the only company to receive a 'Buy' rating, reflecting market recognition of its long-term potential.
- Competitor Performance: Following Centene, Alignment Healthcare (ALHC) and UnitedHealth Group (UNH) scored 3.32 and 3.28 respectively, indicating relatively lower market confidence in these competitors, which may impact their future market share.
- Market Environment Challenges: With the Trump administration planning to withhold $259 million in Medicaid payments to Minnesota, the external challenges faced by Centene could intensify, further affecting its operational performance and profitability in the ACA market.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
Bio-Techne and UnitedHealth Options Trading Activity Surges
- Bio-Techne Options Volume: Bio-Techne Corp (Ticker: TECH) has seen an options trading volume of 15,116 contracts today, equating to approximately 1.5 million shares, which represents a significant 62.4% of its average daily trading volume over the past month of 2.4 million shares.
- High Volume Contracts: Notably, the $60 strike call option for TECH has recorded a high volume of 5,055 contracts traded today, representing around 505,500 underlying shares, indicating strong market interest at this price level.
- UnitedHealth Options Activity: UnitedHealth Group Inc (Ticker: UNH) has reported an options trading volume of 39,170 contracts today, translating to approximately 3.9 million shares, which is about 47.5% of its average daily trading volume over the past month of 8.3 million shares, reflecting investor focus on its future performance.
- Key Contract Insights: The $300 strike call option for UNH has seen a trading volume of 2,172 contracts today, representing approximately 217,200 shares, suggesting bullish expectations in the market, potentially linked to anticipated future earnings performance.
See More
Centene Stock Declines Amid Membership Losses
- Stock Decline: Centene Corp (NYSE:CNC) shares fell 13.18% to $37.61 on Tuesday, reflecting a 35% drop over the past year, indicating market concerns regarding its future performance.
- Earnings Guidance Reaffirmed: Despite the pressures, Centene reaffirmed its 2026 earnings guidance of over $1.98 per share and adjusted earnings exceeding $3 per share, demonstrating the company's confidence in its future profitability.
- Membership Loss Warning: At the Barclays Global Healthcare Conference, Centene warned of lower membership in some Affordable Care Act (ACA) plans, with attrition expected between the high teens and mid-30s, as noted by CEO Sarah London, who indicated they might exceed this range.
- Increased Utilization Rates: Centene reported a decline in total membership from 28.60 million to 27.63 million for 2025, primarily due to a drop in Medicaid members from 13.00 million to 12.52 million, while higher utilization patterns were noted in specialty pharmacy within the silver tier, indicating shifts in market demand.
See More
